Simulations Plus

Simulations Plus, Inc. provides modeling and simulation software and consulting services supporting drug discovery, development research and regulatory submissions. The firm operates through the Software and Services segment. It designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Simulations Plus reports Q1 revenue decline, eyes global expansion

Simulations Plus (SLP) navigated Q1 challenges with a focus on innovation, growth, and shareholder value.
Balancing revenue streams and exploring global opportunities position the company for future success.
Commitment to science, R&D, and market expansion underscores strategic vision and adaptability.
Positive outlook for future quarters driven by achievements, market traction, and evolving strategies.

Simulations Plus reports solid Q2 earnings, eyes growth opportunities

Simulations Plus delivered a strong quarter with revenue and net income growth.
The company's focus on collaborations and AI technologies bodes well for future growth.
Challenges in certain software products and economic impacts on sales cycles noted.
Opportunities in agrochemicals, biosimilars, and inorganic growth avenues are being pursued.

Simulations Plus (SLP) reports strong Q3 earnings and expands into oncology with Immunetrics acquisition

Simulations Plus (SLP) delivered a robust performance in Q3 2023, driven by revenue growth, strategic acquisitions, and operational initiatives.
While facing challenges such as renewal rate fluctuations, SLP remains well-positioned to capitalize on opportunities for growth and expansion.
Guidance for fiscal 2023, strong backlog visibility, and the Immunetrics acquisition underscore SLP's positive trajectory and potential for sustained success.

Simulations Plus (SLP) posts strong Q4 results, eyes biosimulation growth

Simulations Plus (SLP) delivered a solid performance in Q4 2023, showcasing revenue growth, strong margins, and notable achievements. While facing challenges from market conditions and nonrenewals, the company is optimistic about growth opportunities in biosimulation and revenue contributions from the Immunetrics acquisition.

Simulations Plus (SLP) reports stellar Q1 results and eyes growth

Simulations Plus (SLP) demonstrated robust performance across key segments, with strong revenue growth and profitability metrics.
While facing challenges like varied client budgets and revenue declines in certain units, the company is well-positioned to capitalize on growth opportunities.
With a focus on customer loyalty, operational efficiency, and strategic investments, Simulations Plus is poised for continued success in the market.

Simulations Plus (SLP) reports strong Q2 growth and outlook

Simulations Plus (SLP) demonstrated robust growth in Q2 2024
Strong performance in both Software and Services segments
Positive market outlook and strategic positioning for future growth
Focused on meeting fiscal 2024 guidance targets

Simulations Plus Reports Strong Q3, Eyes Growth Initiatives

Simulations Plus delivered a strong performance in Q3 2024, driven by growth in both software and services. The launch of new software and the acquisition of Pro-ficiency highlight strategic moves to enhance offerings and market position. However, challenges in gross margin and client spending patterns could impact future performance. Overall, the company remains focused on growth and operational integration.

Simulations Plus beats earnings expectations, eyes TAM expansion opportunities

Simulations Plus delivered strong financial results, exceeding revenue and EPS expectations. While facing challenges in meeting organic growth targets, the company's strategic investments and acquisitions position it well for future growth. With a focus on expanding TAM and maintaining profitability, Simulations Plus remains optimistic about its prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Simulations Plus, Inc. engages in the provision of software and consulting services supporting drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. The firm operates through the Software and Services segment. The Software segment offers software products for pharmaceutical research, development, and commercialization of the firm's products. The Services segment focuses on contracted consulting studies for customers and offers services supporting marketplace insight and medical communications for clinical and commercial drug development. The company was founded by Walter S. Woltosz and Virginia E. Woltosz on July 17, 1996 and is headquartered in Lancaster, CA.

Craig-Hallum has upgraded Simulations Plus Inc (NASDAQ: SLP) to Buy from Hold with a price target of $53, down from $65.  Related:   Simulations Plus Target Price Lowered At Craig-Hallum, Raymond James After Q3 Sales Miss Expectations.

Why Did Craig-Hallum Upgrade Simulations Plus After Q4 Earnings?

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced a new FDA-funded grant award with the University of Connecticut to enhance mechanistic models for long-acting injectables.

Simulations Plus and the University of Connecticut Awarded New FDA Contract to Accelerate the Development of Long-Acting Injectable Products

Simulations Plus, Inc. (SLP) CEO Shawn O'Connor on Q4 2021 Results - Earnings Call Transcript

Simulations Plus (SLP) delivered earnings and revenue surprises of -87.50% and 20.97%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?

Simulations Plus (SLP) Q4 Earnings Lag Estimates

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus today reported financial results for the 4th quarter & full fiscal year 2021. Total FY21 revenue increased 12% to $46.5 million.

Simulations Plus Reports Fourth Quarter and Full Year Fiscal 2021 Results

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus launched its University+ Program offering students & educators at accredited universities free 1-year access to the company software.

Simulations Plus Announces the University+ Program

Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Simulations Plus (SLP) Q4 Earnings Expected to Decline

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report its 4th quarter and fiscal year 2021 results on Mon., Oct. 25, 2021, with a webcast at 5:00pm ET.

Simulations Plus Sets Date for 4th Quarter and Fiscal Year 2021 Earnings Release and Conference Call

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced a new grant award from the FDA to enhance the predictive power of the mechanistic TCAT model in its flagship GastroPlus.

Simulations Plus Receives New Grant Award From the FDA

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus releases ADMET Predictor 10.3 (APX.3) with key upgrades to its AIDD Module making it the premier program for AI-driven drug design.

Simulations Plus Releases ADMET Predictor® (X.3)

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus will be presenting at BofA Securities Tech Solutions for Drug Discovery and Oppenheimer Fall Healthcare Life Sciences conferences.

Simulations Plus to Participate in BofA Securities and Oppenheimer Investor Conferences

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reports that phase 2 of its AIDD collaboration with a large pharma partner is producing good data validating AIDD in ADMET Predictor.

Simulations Plus Reports Continued Success in Second Phase of AIDD Collaboration with Large Pharmaceutical Company

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced that China's Center for Drug Evaluation of the NMPA has added GastroPlus licenses for research aiding regulatory reviews.

NMPA's Center for Drug Evaluation Adds Licenses of GastroPlus®

Simulations Plus's total return overperformed the Dow average for my 67-month test period by 308.05%, which is great, and the recent dip is a buying opportunity. Simulations Plus's three-year past CAGR of 18.5% is well above average and will give you great growth with the increasing need to test new drugs faster than before.

Simulations Plus: Growth Speculation, Buy The Dip In This Drug Testing Company

Shares of Simulations Plus are currently attractively priced for long term, growth oriented investors. With zero debt, growing earnings and close to $120 million of cash in the bank, the company's financial position has never been stronger in its history.

Searching For Wonderful Businesses: Simulations Plus

Simulations Plus (SLP) Q3 results are hurt by weakness in Services business, stemming from project delays. Software business revenues witness strong growth.

Simulations Plus (SLP) Q3 Earnings Top, Revenues Miss Estimates

Investors weren't happy about hiccups that pressured fiscal third-quarter revenue.

Here's Why Simulations Plus Stock Is Sliding Today

Simulations Plus, Inc. (SLP) CEO Shawn O'Connor on Q3 2021 Results - Earnings Call Transcript

Shares of Simulations Plus (NASDAQ:SLP) rose fell in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 10.00% year over year to $0.18, which were in line with the estimate of $0.18.

Simulations Plus: Q3 Earnings Insights

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus reported financial results for the 3rd quarter of FY21. Total revenue increased 4% to $12.8 million with software revenue up by 21%.

Simulations Plus Reports Third Quarter Fiscal 2021 Financial Results

Simulations Plus (SLP) fiscal third-quarter performance is likely to reflect gains from strength in its diversified portfolio that includes offerings like GastroPlus, DDDPlus and PKPlus.

Simulations Plus (SLP) to Post Q3 Earnings: What's in Store?

On Monday, July 12, Simulations Plus (NASDAQ:SLP) will release its latest earnings report. Decipher the announcement with Benzinga's help.

Simulations Plus Earnings Preview

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus is celebrating its 25th year in business with a series of events designed to thank our valued clients, employees, and shareholders.

Simulations Plus Celebrates 25 Years in Business

Earnings Preview: Simulations Plus (SLP) Q3 Earnings Expected to Decline

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus announced today that it will report its 3rd quarter fiscal year 2021 results on Monday, July 12, 2021, with a webcast at 1:15 pm ET.

News for Simulations Plus Stock (SLP)